Your browser is no longer supported. Please, upgrade your browser.
Jazz Pharmaceuticals plc
Index- P/E- EPS (ttm)-2.55 Insider Own2.80% Shs Outstand61.28M Perf Week-8.20%
Market Cap8.20B Forward P/E7.53 EPS next Y17.41 Insider Trans-2.40% Shs Float59.89M Perf Month2.22%
Income-160.90M PEG- EPS next Q3.59 Inst Own97.40% Short Float7.42% Perf Quarter-8.16%
Sales2.86B P/S2.86 EPS this Y-53.60% Inst Trans0.54% Short Ratio7.15 Perf Half Y-24.56%
Book/sh64.27 P/B2.04 EPS next Y11.04% ROA-1.70% Target Price203.15 Perf Year-21.08%
Cash/sh10.74 P/C12.20 EPS next 5Y17.65% ROE-4.10% 52W Range117.64 - 189.00 Perf YTD2.86%
Dividend- P/FCF10.71 EPS past 5Y-4.20% ROI5.90% 52W High-30.67% Beta0.85
Dividend %- Quick Ratio2.00 Sales past 5Y12.30% Gross Margin87.60% 52W Low11.39% ATR4.71
Employees1940 Current Ratio3.60 Sales Q/Q39.50% Oper. Margin10.30% RSI (14)43.34 Volatility3.53% 3.13%
OptionableYes Debt/Eq1.60 EPS Q/Q-132.70% Profit Margin-5.60% Rel Volume1.27 Prev Close135.67
ShortableYes LT Debt/Eq1.59 EarningsNov 09 AMC Payout- Avg Volume621.04K Price131.04
Recom1.70 SMA20-3.97% SMA500.28% SMA200-12.93% Volume785,959 Change-3.41%
Nov-19-21Resumed Goldman Buy $198
Oct-07-21Resumed Jefferies Buy $172
Oct-05-21Initiated Citigroup Buy $200
Sep-23-21Initiated Needham Buy $220
May-19-21Resumed JP Morgan Overweight $183 → $206
Apr-07-21Resumed RBC Capital Mkts Outperform $186
Feb-05-21Reiterated H.C. Wainwright Buy $195 → $207
Feb-03-21Upgrade Piper Sandler Neutral → Overweight $150 → $175
Jan-29-21Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-16-20Initiated UBS Buy $174
Nov-03-20Reiterated H.C. Wainwright Buy $185 → $195
Oct-09-20Reiterated H.C. Wainwright Buy $175 → $185
Sep-14-20Resumed JP Morgan Overweight $175
Sep-14-20Downgrade Goldman Neutral → Sell $128
Aug-06-20Upgrade Morgan Stanley Equal-Weight → Overweight $177
Jul-28-20Upgrade Wolfe Research Peer Perform → Outperform
Jul-23-20Upgrade H.C. Wainwright Neutral → Buy
Apr-06-20Initiated Jefferies Buy $149
Mar-12-20Upgrade Bernstein Mkt Perform → Outperform $166
Jan-08-20Initiated Goldman Neutral $153
Jan-21-22 09:38AM  
Jan-20-22 01:38PM  
Jan-19-22 01:38PM  
Jan-17-22 10:00AM  
Jan-14-22 11:15AM  
Jan-11-22 10:46AM  
Jan-10-22 07:30AM  
Jan-05-22 07:45AM  
Jan-04-22 12:38PM  
Jan-03-22 04:15PM  
Dec-31-21 09:33AM  
Dec-30-21 07:45AM  
Dec-25-21 06:38AM  
Dec-23-21 07:38AM  
Dec-16-21 10:26AM  
Dec-15-21 07:38PM  
Dec-14-21 10:50AM  
Dec-13-21 11:38PM  
Dec-12-21 09:00AM  
Dec-11-21 12:38AM  
Dec-10-21 10:56AM  
Dec-09-21 11:15AM  
Dec-08-21 07:38PM  
Dec-06-21 04:38PM  
Dec-01-21 01:38PM  
Nov-30-21 08:00AM  
Nov-27-21 08:00AM  
Nov-21-21 07:30AM  
Nov-18-21 10:56AM  
Nov-16-21 12:12PM  
Nov-10-21 09:02AM  
Nov-09-21 07:15PM  
Nov-04-21 11:04AM  
Nov-01-21 12:37PM  
Oct-30-21 11:15AM  
Oct-26-21 04:15PM  
Oct-25-21 03:01PM  
Oct-24-21 05:09AM  
Oct-23-21 10:55AM  
Oct-22-21 05:52AM  
Oct-20-21 12:10PM  
Oct-13-21 08:50AM  
Oct-12-21 10:45AM  
Sep-22-21 06:09AM  
Sep-13-21 04:15PM  
Sep-08-21 04:15PM  
Sep-02-21 11:31AM  
Aug-31-21 11:47AM  
Aug-27-21 05:51AM  
Aug-19-21 09:49AM  
Aug-13-21 09:54AM  
Aug-12-21 02:58PM  
Aug-11-21 01:12PM  
Aug-10-21 04:24AM  
Aug-04-21 10:35AM  
Aug-03-21 11:01PM  
Aug-02-21 01:31PM  
Jul-30-21 09:17AM  
Jul-27-21 03:03PM  
Jul-25-21 05:42AM  
Jul-24-21 06:19AM  
Jul-22-21 04:15PM  
Jul-20-21 04:15PM  
Jul-16-21 02:08PM  
Jul-13-21 04:15PM  
Jul-07-21 10:15AM  
Jul-06-21 06:17PM  
Jul-05-21 05:30AM  
Jul-01-21 10:00AM  
Jun-30-21 08:04PM  
Jun-29-21 07:02AM  
Jun-28-21 03:48PM  
Jun-25-21 07:45AM  
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COZADD BRUCE CChairman & CEOJan 03Option Exercise46.839,700454,251328,251Jan 05 04:36 PM
COZADD BRUCE CChairman & CEOJan 03Sale127.855,791740,387322,460Jan 05 04:36 PM
Smith Mark DouglasDirectorDec 02Sale121.3041750,5824,419Dec 06 07:17 PM
Cook Jennifer E.DirectorDec 02Sale121.3041750,5824,419Dec 06 07:13 PM
COZADD BRUCE CChairman & CEODec 01Option Exercise46.839,700454,251325,299Dec 03 04:52 PM
COZADD BRUCE CChairman & CEODec 01Sale122.666,748827,726318,551Dec 03 04:52 PM
Larkin FinbarSVP, Technical OperationsNov 12Sale135.7919726,75116,468Nov 16 04:13 PM
Sablich KimEVP & GM, North AmericaNov 11Sale135.012,748371,00021,135Nov 15 07:30 PM
COZADD BRUCE CChairman & CEONov 01Option Exercise46.839,700454,251322,092Nov 03 04:43 PM
COZADD BRUCE CChairman & CEONov 01Sale134.756,556883,391315,536Nov 03 04:43 PM
COZADD BRUCE CChairman & CEOOct 04Option Exercise46.839,700454,251318,990Oct 06 04:58 PM
COZADD BRUCE CChairman & CEOOct 04Sale129.876,598856,903312,392Oct 06 04:58 PM
Larkin FinbarSVP, Technical OperationsSep 08Sale134.51638,47416,579Sep 10 04:01 PM
COZADD BRUCE CChairman & CEOSep 01Sale131.5850065,790309,290Sep 03 04:57 PM
Winningham Rick EDirectorAug 06Sale147.961,306193,2367,138Aug 10 05:42 PM
Sohn Catherine A.DirectorAug 06Sale147.961,306193,23611,562Aug 10 05:40 PM
RIEDEL NORBERT GDirectorAug 06Sale147.961,306193,23610,399Aug 10 05:38 PM
O'Keefe Kenneth WDirectorAug 06Sale147.961,306193,23619,607Aug 10 05:37 PM
McSharry Heather AnnDirectorAug 06Sale147.961,414209,21511,165Aug 10 05:35 PM
Gray PeterDirectorAug 06Sale147.961,414209,21512,852Aug 10 05:34 PM
Carr PatriciaSVP, Finance & PAOAug 06Sale147.9615723,2306,035Aug 10 05:31 PM
COZADD BRUCE CChairman & CEOAug 05Option Exercise46.832,652124,193309,790Aug 09 06:32 PM
Schnee ElmarDirectorAug 05Sale154.001,632251,3288,270Aug 09 06:40 PM
BERNS PAUL LDirectorAug 05Sale154.001,450223,3008,290Aug 09 06:37 PM
COZADD BRUCE CChairman & CEOAug 02Sale169.981,750297,470307,138Aug 04 05:08 PM
COZADD BRUCE CChairman & CEOJul 01Sale180.6710,8501,960,269308,888Jul 06 06:27 PM
COZADD BRUCE CChairman & CEOJun 01Sale179.071,750313,372319,738Jun 03 05:17 PM
COZADD BRUCE CChairman & CEOMay 05Sale170.0050085,000321,341May 05 07:03 PM
COZADD BRUCE CChairman & CEOMay 03Sale164.241,500246,360321,841May 05 07:03 PM
COZADD BRUCE CChairman & CEOApr 01Sale164.961,500247,440323,341Apr 06 06:13 PM
Carr PatriciaVP, Finance & PAOMar 09Sale161.50961155,2026,045Mar 10 04:25 PM
Larkin FinbarSVP, Technical OperationsMar 08Sale161.601,509243,85916,519Mar 10 04:27 PM
Carr PatriciaVP, Finance & PAOMar 08Sale161.611,089175,9887,006Mar 10 04:25 PM
COZADD BRUCE CChairman & CEOMar 01Sale170.009,6001,632,000346,357Mar 03 04:27 PM
COZADD BRUCE CChairman & CEOFeb 03Sale160.0025040,000318,032Feb 03 06:00 PM
COZADD BRUCE CChairman & CEOFeb 01Sale156.151,250195,188318,282Feb 03 06:00 PM